A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment
Archives of Dermatological Research · 2025
DOI: 10.1007/s00403-025-04151-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Wenting Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Affiliated to, Hangzhou Third People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Vitiligo, Pyrimidines, Janus Kinase Inhibitors, Piperidines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Oral Janus Kinase (JAK) inhibitors represent a significant advancement in the treatment of vitiligo; however, large-scale clinical data on their optimal treatment duration and efficacy remain limited. This study aimed to evaluate the efficacy and safety of the oral JAK inhibitor tofacitinib in patients with active vitiligo over a 3-month period. A retrospective analysis was conducted on patients diagnosed with active vitiligo between June 2023 and January 2024 who received oral tofacitinib for at least 3 months. Data were extracted from patient records. Vitiligo activity was assessed based on the Vitiligo Disease Activity (VIDA) score in combination with specific clinical manifestations, while treatment efficacy was evaluated based on the Vitiligo Area Severity Index (VASI). Safety data were reviewed retrospectively throughout the treatment period. A total of 137 patients were included in the study. The VIDA score improved from 2.75 ± 1.15 at baseline to 1.63 ± 0.66 at treatment discontinuation, with 59.1% (81/137) of patients achieving disease stabilization. The baseline VASI score was 3.79 (1.54-4.0), which decreased to 2.68 (1.0-2.92), reflecting an overall 29.3% improvement. After 3 months of treatment, 98 patients continued to take tofacitinib. Patients who received treatment for 6-9 months demonstrated significantly greater repigmentation (42.27% improvement) compared to those treated for less than 6 months (P < 0.05). No significant differences in efficacy were observed between non-segmental and segmental vitiligo. Mild adverse reactions were reported in 13.8% of patients, primarily including gastrointestinal discomfort, acne, elevated liver enzymes, and palpitations, with no severe adverse events recorded. In conclusion, oral tofacitinib administered for 3 months effectively stabilized vitiligo progression, while treatment extending to 6-9 months results in greater repigmentation and maintained a favorable safety profile. Further long-term controlled studies are warranted to validate these findings and optimize treatment strategies. Trial registration: http://www.chictr.org.cn . identifier: ChiCTR2400092326.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Affiliated to, Hangzhou Third People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
- School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Dermatology, Affiliated to, Hangzhou Third People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China. xuaiehz@hotmail.com.
Zitieren
APA
Hu, W., Cao, C., Zheng, Y., Lei, J., Yu, K., Sheng, A., Jin, R., & Xu, A. E. (2025). A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-04151-9
Vancouver
Hu W, Cao C, Zheng Y, Lei J, Yu K, Sheng A, et al. A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment. Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-04151-9
BibTeX
@article{Hu2025,
author = {Hu, Wenting and Cao, Cheng and Zheng, Yujie and Lei, Jindi and Yu, Keyi and Sheng, Anqi and Jin, Rong and Xu, Ai-E},
title = {A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment},
journal = {Archives of Dermatological Research},
year = {2025},
doi = {10.1007/s00403-025-04151-9}
}
EUVIMED